This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wozniacka, A Articles by Mccauliffe, D P Search for Related Content PubMed PubMed Citation Articles by Wozniacka, A Articles by Mccauliffe, D P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE Social Bookmarking                         What's this?

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit

Department of Dermatology, Medical University of Lodz, Lodz, Krzemieniecka, Poland

A Carter

Medical School, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

D P Mccauliffe

Department of Medicine, Division of Dermatology, Box 3135, Duke University Medical Center, Durham, NC 27710, USA,dpmccauliffe{at}juno.com

Antimalarials are arguably the best modality currently available for treating patients with cutaneous lupus erythematosus (LE). Although antimalarials have been used for decades in treating cutaneous LE, the precise mechanisms by which they provide therapeutic benefit are not well defined. The putative mechanisms by which antimalarials might provide therapeutic benefit to patients with cutaneous LE include a number of interrelated anti-inflammatory and immunosuppressive effects that include photoprotection, lysosomal stabilization, suppression of antigen presentation, and inhibition of prostaglandin and cytokine synthesis. If we had a more precise understanding of how antimalarials provide therapeutic benefit in cutaneous LE we might gain better insight into the pathogenic mechanisms of LE and ways of developing better therapies for afflicted patients.

Key Words: LE • cutaneous • antimalarials • hydroxychloroquine • chloroquine

Lupus, Vol. 11, No. 2, 71-81 (2002)
DOI: 10.1191/0961203302lu147rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I Cavazzana, R Sala, C Bazzani, A Ceribelli, C Zane, R Cattaneo, A Tincani, P. Calzavara-Pinton, and F Franceschini Treatment of lupus skin involvement with quinacrine and hydroxychloroquine Lupus, July 1, 2009; 18(8): 735 - 739. [Abstract] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, J Kobos, S Pavel, and A Sysa-Jedrzejowska Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus Lupus, February 1, 2007; 16(2): 89 - 94. [Abstract] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients Lupus, May 1, 2006; 15(5): 268 - 275. [Abstract] [PDF]

				M. E. Falagas and P. I. Vergidis Narrative Review: Diseases That Masquerade as Infectious Cellulitis Ann Intern Med, January 4, 2005; 142(1): 47 - 55. [Abstract] [Full Text] [PDF]